The FDA will give Pfizer’s COVID-19 vaccine full approval next week, the report said


    Sarah Tew / CNET

    For the latest news and information on the coronavirus pandemic, visit the WHO and CDC websites.

    The US Food and Drug Administration could give complete agreement to Pfizer Coronavirus vaccination According to a report in the New York Times as early as Monday. Regulators reportedly worked Friday to finalize paperwork and negotiations with the company.

    The two-dose Pfizer vaccine is currently being administered in the United States under an emergency clearance granted in December. Pfizer and its partner BioNTech filed for full FDA approval in May. Full approval would allow Pfizer to market its vaccine directly to consumers, as well could make it easier for authorities and schools to make vaccinations mandatory.

    More than 203 million doses of the Pfizer vaccine have been administered in the United States, according to the Centers for Disease Control and Prevention. Last week the FDA and CDC did deregistered on a third shot the Pfizer and Moderna vaccines for some immunocompromised people. And on Wednesday, Biden government health officials said fully vaccinated adults who received the Pfizer or Moderna shots are entitled to a booster shot until next month.

    FDA approval of the Pfizer vaccine could slide beyond Monday, but is expected to come well before the agency’s unofficial Labor Day deadline.

    The FDA declined to comment.

    Modern is also seeking FDA approval for its COVID-19 vaccine, although a decision may reportedly take a few more weeks.

    Currently running:
    Look at that:

    What to do if you lose your vaccination certificate and how …


    The information contained in this article is for educational and informational purposes only and is not intended as health or medical advice. Always consult a doctor or other qualified health care provider with questions about a medical condition or health goals.


    Please enter your comment!
    Please enter your name here